Karyopharm Therapeutics (KPTI) Other Gross PP&E Adjustments (2016 - 2025)
Karyopharm Therapeutics (KPTI) has disclosed Other Gross PP&E Adjustments for 14 consecutive years, with -$1.8 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Other Gross PP&E Adjustments rose 57.55% year-over-year to -$1.8 million, compared with a TTM value of -$1.8 million through Dec 2025, up 57.55%, and an annual FY2025 reading of -$1.8 million, up 57.55% over the prior year.
- Other Gross PP&E Adjustments was -$1.8 million for Q4 2025 at Karyopharm Therapeutics, up from -$4.7 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$1.8 million in Q4 2025 and bottomed at -$12.8 million in Q4 2021.
- Average Other Gross PP&E Adjustments over 5 years is -$6.2 million, with a median of -$5.5 million recorded in 2023.
- Peak annual rise in Other Gross PP&E Adjustments hit 57.55% in 2025, while the deepest fall reached 80.97% in 2025.
- Year by year, Other Gross PP&E Adjustments stood at -$12.8 million in 2021, then increased by 3.91% to -$12.3 million in 2022, then skyrocketed by 54.33% to -$5.6 million in 2023, then rose by 25.82% to -$4.2 million in 2024, then soared by 57.55% to -$1.8 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for KPTI at -$1.8 million in Q4 2025, -$4.7 million in Q3 2025, and -$5.1 million in Q2 2025.